These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15464679)

  • 1. Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).
    Rebeiz AG; Dery JP; Tsiatis AA; O'shea JC; Johnson BA; Hellkamp AS; Pieper KS; Gilchrist IC; Slater J; Muhlestein JB; Joseph D; Kitt MM; Tcheng JE;
    Am J Cardiol; 2004 Oct; 94(7):926-9. PubMed ID: 15464679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.
    Gibson CM; Murphy SA; Marble SJ; Cohen DJ; Cohen EA; Lui HK; Young J; Kitt MM; Lorenz TJ; Tcheng JE
    Am Heart J; 2002 Jan; 143(1):106-10. PubMed ID: 11773919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.
    Blankenship JC; Tasissa G; O'Shea JC; Iliadis EA; Bachour FA; Cohen DJ; Lui HK; Mann T; Cohen E; Tcheng JE;
    J Am Coll Cardiol; 2001 Sep; 38(3):653-8. PubMed ID: 11527612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
    Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
    Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
    Biondi-Zoccai GG; Valgimigli M; Sheiban I; Margheri M; Marzocchi A; Prati F; Vischi M; Lettieri C; Violini R; Sardella G; Stabile A; Clementi F; Romeo F; Colombo A; Sangiorgi G
    J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):957-62. PubMed ID: 18695440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
    Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
    J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of IIb/IIIa inhibitors in patients with in-stent restenosis treated with intracoronary gamma-radiation. Integrilin WRIST.
    Waksman R; Ajani AE; Gruberg L; Pinnow E; GebreEyesus A; Deible R; Satler LF; Pichard AD; Torguson R; Kent KM; Suddath W; Lindsay J
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):162-6. PubMed ID: 15170704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
    Fernandes LS; Tcheng JE; O'Shea JC; Weiner B; Lorenz TJ; Pacchiana C; Berdan LG; Maresh KJ; Joseph D; Madan M; Mann T; Kilaru R; Hochman JS; Kleiman NS;
    J Am Coll Cardiol; 2002 Sep; 40(6):1085-91. PubMed ID: 12354432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
    Ronner E; Boersma E; Akkerhuis KM; Harrington RA; Lincoff AM; Deckers JW; Karsch K; Kleiman NS; Vahanian A; Topol EJ; Califf RM; Simoons ML
    Eur Heart J; 2002 Feb; 23(3):239-46. PubMed ID: 11792139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
    Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
    Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
    O'Shea JC; Buller CE; Cantor WJ; Chandler AB; Cohen EA; Cohen DJ; Gilchrist IC; Kleiman NS; Labinaz M; Madan M; Hafley GE; Califf RM; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2002 Feb; 287(5):618-21. PubMed ID: 11829701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience.
    Cantor WJ; Tcheng JE; Blankenship JC; O'Shea JC; Pieper KS; Criger DA; Madan M; Ducas J; Sheldon WS; Tannenbaum MA; Smith JE; Kitt MM; Gilchrist IC
    J Invasive Cardiol; 2004 Sep; 16(9):475-81. PubMed ID: 15353828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.
    O'Shea JC; Hafley GE; Greenberg S; Hasselblad V; Lorenz TJ; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2001 May; 285(19):2468-73. PubMed ID: 11368699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Curran MP; Keating GM
    Drugs; 2005; 65(14):2009-35. PubMed ID: 16162023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
    ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
    Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial.
    Blankenship JC; Sigmon KN; Pieper KS; O'Shea C; Tardiff BE; Tcheng JE;
    Am J Cardiol; 2001 Nov; 88(9):969-73. PubMed ID: 11703991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
    Akkerhuis KM; Deckers JW; Boersma E; Harrington RA; Stepinska J; Mahaffey KW; Wilcox RG; Lincoff AM; Keltai M; Topol EJ; Califf RM; Simoons ML
    Eur Heart J; 2000 Mar; 21(5):371-81. PubMed ID: 10666351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.